Abstract
The failure to treat metastatic cancer with multidrug resistance is a major problem for successful cancer therapy, and the molecular basis for the association of metastatic phenotype with resistance to therapy is still unclear. In this study, we revealed that various metastatic cancer cells showed consistently higher levels of antiapoptotic proteins, including Bcl-2, nuclear factor-κB, MDM2, DNA-dependent protein kinase (DNA-PK), and epidermal growth factor receptor (EGFR), and lower levels of proapoptotic proteins, including Bax and p53 than low metastatic parental cells. This was followed by chemo- and radioresistance in metastatic cancer cells compared with their parental cells. EGFR and DNA-PK activity, which are known to be associated with chemo- and radioresistance, were demonstrated to be mutually regulated by each other. Treatment with PKI166, an EGFR inhibitor, suppressed etoposide-induced activation of DNA-PK in A375SM metastatic melanoma cells. In addition, PKI166 enhanced markedly the chemosensitivities of metastatic cancer cell sublines to various anticancer drugs in comparison with those of low metastatic cancer cells. These results suggest that the activities of DNA-PK and EGFR, which is positively correlated with each other, may contribute to metastatic phenotype as well as therapy resistance, and the EGFR inhibitor enhances the effect of anticancer drugs against therapy-resistant metastatic cancer cells via suppression of stress responses, including activation of DNA-PK.
Footnotes
-
doi:10.1124/jpet.104.070938.
-
ABBREVIATIONS: EGFR, epidermal growth factor receptor; DNA-PK, DNA-dependent protein kinase; DNA-PKcs, DNA-dependent protein kinase catalytic subunit; VBL, vinblastine; VCR, vincristine; CPT, camptothecin; DOX, doxorubicin; BLM, bleomycin; VP-16, etoposide; FBS, fetal bovine serum; DMEM, Dulbecco's modified Eagle's medium; MEF, murine embryonic fibroblast; NF-κB, nuclear factor-κB; MTT, 3-(4,5-dimethylthiazol-2-yl)2,5-diphenyl-tetrazolium bromide; EMSA, electrophoretic mobility shift analysis; MDR, multidrug resistance.
-
↵1 Current address: Department of Otolaryngology, College of Medicine, University of Ulsan, Ulsan, Korea.
- Received May 3, 2004.
- Accepted July 22, 2004.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|